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ORIGINAL ARTICLE

Uptake of Adjuvant Durvalumab After Definitive
Concurrent Chemoradiotherapy for Stage III
Nonsmall-cell Lung Cancer
Alex K. Bryant, MD, MAS,* Huiying Yin, MS,† Matthew J. Schipper, PhD,*†
Peter A. Paximadis, MD,‡ Thomas P. Boike, MD,§ Derek P. Bergsma, MD,∥
Benjamin Movsas, MD,¶ Robert T. Dess, MD,* Melissa A. Mietzel, MS,*
Randi Kendrick, MS,* Merita Seferi, BS,* Michael M. Dominello, DO,#
Martha M. Matuszak, PhD,* Reshma Jagsi, MD, DPhil,* James A. Hayman, MD,*
Lori J. Pierce, MD,* and Shruti Jolly, MD,*
on behalf of the Michigan Radiation Oncology Quality Consortium

Objectives: The addition of adjuvant durvalumab improves overall
survival in locally advanced nonsmall-cell lung cancer (NSCLC)
patients treated with deﬁnitive chemoradiation, but the real-world
uptake of adjuvant durvalumab is unknown.
Materials and Methods: We identiﬁed patients with stage III NSCLC
treated with deﬁnitive concurrent chemoradiation from January 2018 to
October 2020 from a statewide radiation oncology quality consortium,
representing a mix of community (n = 22 centers) and academic (n = 5)
across the state of Michigan. Use of adjuvant durvalumab was ascertained at the time of routine 3-month or 6-month follow-up after
completion of chemoradiation.
Results: Of 421 patients with stage III NSCLC who completed chemoradiation, 322 (76.5%) initiated adjuvant durvalumab. The percentage of
patients initiating adjuvant durvalumab increased over time from 66% early
in the study period to 92% at the end of the study period. There was
substantial heterogeneity by treatment center, ranging from 53% to 90%. In
multivariable logistic regression, independent predictors of durvalumab
initiation included more recent month (odds ratio [OR]: 1.05 per month,
95% conﬁdence interval [CI]: 1.02-1.08, P = 0.003), lower Eastern
Cooperative Oncology Group score (OR: 4.02 for ECOG 0 vs. 2+, 95%
CI: 1.67-9.64, P = 0.002), and a trend toward signiﬁcance for female sex
(OR: 1.66, 95% CI: 0.98-2.82, P = 0.06).
Conclusion: Adjuvant durvalumab for stage III NSCLC treated with
deﬁnitive chemoradiation was rapidly and successfully incorporated
into clinical care across a range of community and academic settings in
the state of Michigan, with over 90% of potentially eligible patients
starting durvalumab in more recent months.
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A

djuvant durvalumab after deﬁnitive concurrent chemoradiation for unresectable stage III nonsmall-cell lung
cancer (NSCLC) became the standard-of-care after the publication of PACIFIC in 2018, which showed an 11% absolute
overall survival beneﬁt at 2 years compared with placebo.1,2
Durvalumab was approved by the Federal Drug Administration
(FDA) for this indication on February 16, 2018, but it is unclear
how quickly durvalumab has been incorporated into routine
care since approval. In this study we studied the rate of adjuvant
durvalumab initiation in a diverse consortium of community
and academic radiation oncology practices across the state of
Michigan.

MATERIALS AND METHODS
Data Source and Patient Selection
We identiﬁed patients with newly diagnosed stage III
(American Joint Committee on Cancer 8th edition) NSCLC
treated with deﬁnitive concurrent chemoradiation through
the Michigan Radiation Oncology Quality Consortium
(MROQC). MROQC is a statewide quality improvement effort
that tracks implementation of best practices in radiation
oncology across a range of academic and community centers
in Michigan. Patient-level demographic, comorbidity, staging,
treatment, and toxicity data are collected within a centralized
database by trained data abstractors. As durvalumab was
approved as adjuvant therapy in stage III NSCLC on February
16, 2018, we included patients who started deﬁnitive chemoradiation between January 31, 2018 through October 1, 2020.
The database was last updated on April 30, 2021 to allow
adequate time for follow-up in assessing adjuvant therapy
initiation. Among 1908 stage III NSCLC patients, we
excluded patients treated with radiotherapy outside of the date
window (n = 1245), patients treated with radiation alone or
surgery following radiation (n = 132), missing adjuvant therapy information (n = 63), and patients treated with immunotherapy other than durvalumab (n = 47), leaving a ﬁnal cohort
of 421 patients. This study was institutional review board
exempt.
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TABLE 1. Characteristics of the Sample

Variable
Sample size
Age in years, mean (SD)
Male
Race
Caucasian
African American
Other
Insurance
Medicare
Medicaid
Commercial
Other
Uninsured
Married
Academic hospital setting
Supplemental O2 at baseline
ECOG
0
1
2+
Unknown
Smoking
Current
Former
Unknown
Comorbidities
Hypertension
Diabetes
COPD
Cardiac disease*
Connective tissue disease†
Vascular disease‡
Renal disease
Liver disease
Other malignancy
Histology
Adenocarcinoma
Squamous cell carcinoma
AJCC 8th summary
stage
IIIA
IIIB
Tumor stage
T1
T2
T3
T4
Nodal stage
N0
N1
N2
N3
NX
Cumulative
radiation dose
< 59 Gy
60-65 Gy
> 65 Gy
Unknown

Durvalumab, n (%)

No Durvalumab, n (%)

P

322 (76.5)
65.5 (8.56)
173 (53.7)

99 (23.5)
67.4 (10.2)
59 (59.6)

0.06
0.31

277 (86.0)
34 (10.6)
11 (3.42)

84 (84.9)
12 (12.1)
3 (3.03)

0.90

149
32
77
64

(46.3)
(9.94)
(23.9)
(19.9)
0
156 (48.5)
47 (14.6)
27 (8.39)

47
8
25
18
1
45
13
10

(47.5)
(8.08)
(25.3)
(18.2)
(1.01)
(45.5)
(13.1)
(10.1)

0.45

184
107
17
14

52
23
17
7

(52.5)
(23.2)
(17.2)
(7.07)

(57.1)
(33.2)
(5.28)
(4.35)

0.60
0.72
0.60
0.001

141 (43.8)
166 (51.6)
15 (4.66)

29 (29.3)
62 (62.6)
8 (8.08)

0.03

187
66
160
51
5
32
17
11
20

65
17
46
18
4
10
6
4
11

(65.7)
(17.2)
(46.5)
(18.2)
(4.04)
(10.1)
(6.06)
(4.04)
(11.1)

0.18
0.47
0.58
0.58
0.14
0.96
0.77
0.77
0.10

151 (46.9)
171 (53.1)

40 (40.4)
59 (59.6)

0.26

201 (62.4)
121 (37.6)

68 (68.7)
31 (31.3)

0.26

54
68
63
137

(16.8)
(21.1)
(19.6)
(42.6)

12
26
21
40

(12.1)
(26.3)
(21.2)
(40.4)

0.55

42
18
197
65

(13.0)
(5.59)
(61.2)
(20.2)
0

9
12
62
15
1

(9.09)
(12.1)
(62.6)
(15.2)
(1.01)

0.04

9
211
88
14

(2.80)
(65.5)
(27.3)
(4.35)

8
61
24
6

(8.08)
(61.6)
(24.2)
(6.06)

0.10

(58.1)
(20.5)
(49.7)
(15.8)
(1.55)
(9.94)
(5.28)
(3.42)
(6.21)

*Cardiac disease includes congestive heart failure, arrhythmia, and prior myocardial infarction.
†Connective tissue disease includes scleroderma, lupus, rheumatoid arthritis, and other connective tissue disease.
‡Vascular disease includes cerebrovascular disease, peripheral vascular disease, or hemiplegia.
AJCC indicates American Joint Committee on Cancer; COPD, chronic obstructive pulmonary disease; ECOG, Eastern Cooperative Oncology Group; Gy, Gray.
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Percent of patients receiving adjuvant durvalumab per institution
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FIGURE 1. Adjuvant durvalumab therapy initiation rates. Rates of adjuvant durvalumab initiation over time (A) and within individual
treatment centers (B). The analysis by treatment center was restricted to the 16 centers (of 27 total) that treated at least 15 patients over
the study period. Error bars represent 95% confidence interval.

Outcomes and Covariates
The primary outcome was initiation of adjuvant durvalumab after completion of deﬁnitive chemoradiation. This was
assessed through physician-completed forms at routine 1, 3, and
6-month follow-up after completion of chemoradiation.

TABLE 2. Results of Multivariable Logistic Regression for Odds of
Initiating Durvalumab

Variable
Age (per 10 y)
Month of follow-up
(per month)
Female sex
Academic hospital setting
Married
Race
Caucasian
African American
Other
Tumor stage
T1
T2
T3
T4
Nodal stage
0
1
2
3
Supplemental oxygen at
baseline
COPD
Diabetes
Cardiac comorbidity
ECOG performance status
0
1
2+

OR for Initiating Durvalumab
(95% CI)

P

0.81 (0.61-1.07)
1.05 (1.02-1.08)

0.14
0.003

1.66 (0.98-2.82)
1.21 (0.58-2.54)
1.02 (0.60-1.72)

0.06
0.61
0.95

(ref)
0.65 (0.29-1.42)
0.91 (0.22-3.75)

(ref)
0.28
0.89

(ref)
0.62 (0.27-1.44)
0.75 (0.32-1.76)
1.12 (0.46-2.75)

0.27
0.5
0.8

(ref)
(0.13-1.27)
(0.34-2.38)
(0.50-4.72)
(0.44-2.74)

(ref)
0.12
0.82
0.46
0.84

1.25 (0.74-2.12)
1.45 (0.76-2.77)
0.77 (0.40-1.49)

0.41
0.26
0.44

(ref)
1.30 (0.73-2.33)
0.25 (0.10-0.60)

(ref)
0.37
0.002

0.40
0.89
1.53
1.10

Odds ratio > 1 indicates greater odds of initiating durvalumab.
CI indicates conﬁdence interval; COPD, chronic obstructive pulmonary disease; ECOG, Eastern Cooperative Oncology Group; OR, odds ratio.

Baseline covariates assessed before the start of chemoradiation
included age, sex, race, insurance, married status, academic
versus community center setting, smoking status, Eastern
Cooperative Oncology Group (ECOG) performance status, use
of supplemental oxygen, baseline comorbidities (hypertension,
diabetes, chronic obstructive pulmonary disease, cardiac disease [including congestive heart failure, arrhythmia, or prior
myocardial infarction], connective tissue disease, vascular disease including prior stroke, peripheral arterial disease, hemiplegia, renal disease, liver disease, or other malignancy), tumor
histology (adenocarcinoma vs. squamous cell), tumor stage,
nodal stage, and cumulative radiation dose planned to the
primary tumor.

Statistics
Baseline demographics and treatment information were
compared with the t test for continuous variables and the χ2 test
for categorical variables. We modeled the odds of adjuvant
immunotherapy initiation using multivariable logistic regression. Predictors in the model were chosen a priori and included
age, calendar quarter, sex, academic hospital setting, marriage
status, race, tumor stage, nodal stage, use of supplemental
oxygen at baseline, chronic obstructive pulmonary disease,
diabetes, cardiac disease, and ECOG score. Analyses were
performed with SAS 9.4 (SAS Institute, Cary, NC) and R 4.0.4
(R Core Team, Vienna, Australia).

RESULTS
The cohort included 421 patients with stage III NSCLC
treated with deﬁnitive chemoradiation, of whom 322 (76.5%)
initiated adjuvant durvalumab. The cohort spanned 27 treatment
centers in total, 5 of which were associated with an academic
hospital setting (accounting for 14% of the patient cohort). The
cohort was predominately Caucasian (85.7%) with excellent
performance status (86.9% with ECOG 0 or 1); the mean age
was 65.9 years (SD: 8.9). Patients who did not receive adjuvant
durvalumab were slightly older (mean age: 67.4 vs. 65.5 years,
P = 0.06), had worse performance status (17.2% vs. 5.3% with
ECOG 2 or higher, P = 0.001), and were less likely to be current smokers (29.3% vs. 43.8%, P = 0.03) compared with
patients who received durvalumab. The groups were otherwise
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broadly similar in demographic, stage, and comorbidity proﬁles
(Table 1).
The percentage of patients receiving adjuvant durvalumab
increased over time, from 66% (95% conﬁdence interval [CI]:
50%-81%) at the beginning of the study period to 92% (95%
CI: 78%-100%) in the most recent quarter (mean 2.5% increase
per quarter, P = 0.006 for correlation; Fig. 1A). There was
heterogeneity in this percentage across the 16 centers that
treated at least 15 patients over the study period, from 53%
(95% CI: 28%-79%) to 90% (95% CI: 80%-100%) (Fig. 1B). In
multivariable logistic regression, independent predictors of
durvalumab initiation included more recent month (odds ratio
[OR]: 1.05 per month, 95% CI: 1.02-1.08, P = 0.003) and
worse performance status (OR: 4.02 for ECOG 0 vs. 2+, 95%
CI: 1.67-9.64, P = 0.002). Female sex trended toward signiﬁcance (OR: 1.66, 95% CI: 0.98-2.82, P = 0.06) (Table 2).

DISCUSSION
In this study of contemporary practice patterns in the
state of Michigan, we found that adjuvant durvalumab was
quickly introduced into routine practice after FDA approval.
The percentage of potentially eligible patients who started
durvalumab increased substantially over time and varied
across the 27 treatment centers in the study, though patients
treated at community centers were just as likely to receive
durvalumab as those treated at academic centers. Patients
who did not receive durvalumab tended to be male and to
have worse performance status before chemoradiation, but
there were reassuringly no other differences by race, insurance
status, or comorbidity.
These ﬁndings suggest that durvalumab is being successfully incorporated into routine care across a range of
practice settings and reﬂect the rapid uptake seen after immunotherapy approvals for metastatic tumors in other studies.3,4
The rapid pace of uptake may be inﬂuenced by providers’
previous experience administering immunotherapy, the large
survival beneﬁt seen in PACIFIC, and information dissemination on new standard-of-care practices by MROQC. Within
MROQC, FDA approval of durvalumab in stage III NSCLC
was discussed during lung working group calls as well as
consortium-wide meetings. Each disease site has an assigned
clinical champion who is charged with disseminating relevant
information to their clinics, and these data are then shared with
the consortium physician members. Further, when there are
changes made in elements of data collection, these are reviewed
in detail with clinical coordinators and care providers. Since the
addition of durvalumab is considered level 1 evidence, this was
not speciﬁcally included in the quality consortium consent.
While some concern has been raised about the proportion
of real-world stage III NSCLC patients who are eligible for
durvalumab under strict PACIFIC inclusion criteria,5 we found
that over 90% of our cohort started adjuvant durvalumab in the
most recent months of our study period. Similarly, despite the
substantial economic cost of 12 months of durvalumab
infusions,6 there was no difference in the odds of receiving
durvalumab by insurance status. This may reﬂect recognition of
the likely cost-effectiveness of adjuvant durvalumab relative to
the costs of disease progression, including expensive salvage
chemoimmunotherapy regimens and hospital care.6 Of note, our
data do not include patient-level ﬁnancial toxicity in the form of
potentially signiﬁcant out-of-pocket costs.7,8 Overall our ﬁndings

Definitive Concurrent Chemoradiotherapy

are reassuring that consolidation durvalumab—which carries a
substantial survival beneﬁt1—is reaching most eligible patients
regardless of demographics, insurance coverage, or geography.
Limitations include the predominately Caucasian cohort
and single state setting in Michigan, which may limit generalizability. Further, the limited number of patients who did not
start durvalumab (99 patients) limits our power to detect more
subtle differences in comorbidity or demographic proﬁles that
may inﬂuence durvalumab initiation. Given the consortium’s
focus on educating practitioners on changes in the standardof-care, it is possible that MROQC itself may have caused
increased uptake or that those participating in the consortium
elected to do so because they embrace changes in the standardof-care more readily than others, such that durvalumab use may
be lower among providers outside of the consortium. Finally,
we did not have access to patient-level documentation detailing
the reasons why potentially eligible patients did not start durvalumab. As MROQC does not routinely collect data on disease
progression, it is possible that a subset of patients had progression after deﬁnitive chemoradiation and were therefore
ineligible. Additional avenues of investigation using these data
could include the effect of durvalumab on patient-reported
symptoms, adverse events, and quality of life, which are collected by MROQC at regular intervals. Analysis of quality of
life data from PACIFIC9 suggested no clinically signiﬁcant
differences between treatment arms, though toxicity and quality
of life proﬁles could differ in real-world populations.

REFERENCES
1. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with
durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J
Med. 2018;379:2342–2350.
2. Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival
outcomes with durvalumab after chemoradiotherapy in unresectable
stage III NSCLC: an update from the PACIFIC trial. J Clin Oncol.
2021;39(suppl):8511–8511.
3. O’Connor JM, Fessele KL, Steiner J, et al. Speed of adoption of
immune checkpoint inhibitors of programmed cell death 1 protein
and comparison of patient ages in clinical practice vs pivotal clinical
trials. JAMA Oncol. 2018;4:e180798.
4. Khozin S, Miksad RA, Adami J, et al. Real-world progression,
treatment, and survival outcomes during rapid adoption of
immunotherapy for advanced non-small cell lung cancer. Cancer.
2019;125:4019–4032.
5. Sakaguchi T, Ito K, Furuhashi K, et al. Patients with unresectable
stage III non-small cell lung cancer eligible to receive consolidation
therapy with durvalumab in clinical practice based on PACIFIC
study criteria. Respir Investig. 2019;57:466–471.
6. Criss SD, Mooradian MJ, Sheehan DF, et al. Cost-effectiveness and
budgetary consequence analysis of durvalumab consolidation
therapy vs no consolidation therapy after chemoradiotherapy in
stage III non-small cell lung cancer in the context of the US Health
Care System. JAMA Oncol. 2019;5:358–365.
7. Thom B, Mamoor M, Lavery JA, et al. The experience of financial
toxicity among advanced melanoma patients treated with immunotherapy. J Psychosoc Oncol. 2021;39:285–293.
8. Tran G, Zafar SY. Financial toxicity and implications for cancer care in
the era of molecular and immune therapies. Ann Transl Med. 2018;
6:166–176.
9. Hui R, Özgüroğlu M, Villegas A, et al. Patient-reported outcomes
with durvalumab after chemoradiotherapy in stage III, unresectable
non-small-cell lung cancer (PACIFIC): a randomised, controlled,
phase 3 study. Lancet Oncol. 2019;20:1670–1680.

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

www.amjclinicaloncology.com

Copyright r 2022 Wolters Kluwer Health, Inc. All rights reserved.

| 145

